Role of recombinant human TSH in the management of large euthyroid multinodular goitre: A new therapeutic option? Pros and cons

Minerva Endocrinologica

Volumn 35, Issue 3, 2010, Pages 161-171

  Ceccarelli, C ^a   Brozzi, F ^a   Bianchi, F ^a   Santini, P ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Goiter, nodular; Therapeutics; Thyroid diseases

Indexed keywords

AMIODARONE; IODINE 131; LEVOTHYROXINE; PLACEBO; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; STEROID; THYROID HORMONE; THYROTROPIN;

ACTINIC THYROIDITIS; ADULT; AUTOIMMUNE HYPERTHYROIDISM; BLOOD SAMPLING; CELL ACTIVATION; CERVICAL PAIN; CHEMICAL STRUCTURE; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG UPTAKE; EUTHYROIDISM; GOITER; HEART ATRIUM FIBRILLATION; HEART DISEASE; HOSPITALIZATION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LOW DRUG DOSE; MULTINODULAR GOITER; NODULAR GOITER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTPATIENT; RADIATION; RADIOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEROID THERAPY; SYMPTOM; TACHYCARDIA; THYROID CANCER; THYROID CELL; THYROID FUNCTION; THYROID GLAND; THYROID HORMONE BLOOD LEVEL; THYROIDECTOMY; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL;

GOITER, NODULAR; HUMANS; IODINE RADIOISOTOPES; RADIOMETRY; RECOMBINANT PROTEINS; THYROID GLAND; THYROTROPIN;

EID: 78751615963     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Hegedus L, Hansen BM, Knudsen N, Hansen JM. Reduction of size of thyroid with radioactive iodine in multinodular non-toxic goitre. BMJ 1988;297:661-2.
2. Nygaard B, Hegedus L, Gervil M, Hjalgrim H, Soe-Jensen P, Hansen JM. Radioiodine treatment of multinodular non-toxic goitre. BMJ 1993;307:828-32.
3. Le Moli R, Wesche MF, Tiel-Van Buul MM, Wiersinga WM. Determinants of longterm outcome of radioiodine therapy of sporadic non-toxic goitre. Clin Endocrinol (Oxf) 1999;50:783-9.
4. Huber GK, Fong P, Concepcion ES, Davies TF. Recombinant human thyroid-stimulating hormone: initial bioactivity assessment using human fetal thyroid cells. J Clin Endocrinol Metab 1991;72:1328-31.
5. Braverman LE, Pratt BM, Ebner S, Longcope C. Recombinant human thyrotropin stimulates thyroid function and radioactive iodine uptake in the rhesus monkey. J Clin Endocrinol Metab 1992;74:1135-9.
6. Meier CA, Braverman LE, Ebner SA, Veronikis I, Daniels GH, Ross DS et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab 1994;78:188-96.
7. Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997;337:888-96.
8. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999;84:3877-85.
9. Grossmann M, Weintraub BD, Szkudlinski MW. Novel insights into the molecular mechanisms of human thyrotropin action: structural, physiological, and therapeutic implications for the glycoprotein hormone family. Endocr Rev 1997;18:476-501.
10. Magner JA. Thyroid-stimulating hormone: biosynthesis, cell biology, and bioactivity. Endocr Rev 1990;11:354-85.
11. Torres MS, Ramirez L, Simkin PH, Braverman LE, Emerson CH. Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects. J Clin Endocrinol Metab 2001;86:1660-4.
12. Pena S, Arum S, Cross M, Magnani B, Pearce EN, Oates ME et al. 123I thyroid uptake and thyroid size at 24, 48, and 72 hours after the administration of recombinant human thyroid-stimulating hormone to normal volunteers. J Clin Endocrinol Metab 2006;91:506-10.
13. Fast S, Nielsen VE, Bonnema SJ, Hegedus L. Time to reconsider nonsurgical therapy of benign non-toxic multinodular goitre: focus on recombinant human TSH augmented radioiodine therapy. Eur J Endocrinol 2009;160:517-28.
14. Lawrence JE, Emerson CH, Sullaway SL, Braverman LE. The effect of recombinant human tsh on the thyroid (123)i uptake in iodide treated normal subjects. J Clin Endocrinol Metab 2001;86:437-40.
15. Ramirez L, Braverman LE, White B, Emerson CH. Recombinant human thyrotropin is a potent stimulator of thyroid function in normal subjects. J Clin Endocrinol Metab 1997;82:2836-9.
16. Nielsen VE, Bonnema SJ, Hegedus L. Effects of 0.9 mg recombinant human thyrotropin on thyroid size and function in normal subjects: a randomized, double-blind, cross-over trial. J Clin Endocrinol Metab 2004;89:2242-7.
17. Fast S, Nielsen VE, Bonnema SJ, Hegedus L. Dose-dependent acute effects of recombinant human TSH (rhTSH) on thyroid size and function: comparison of 0.1, 0.3 and 0.9 mg of rhTSH. Clin Endocrinol (Oxf) 2010;72:411-6.
18. Giovanni V, Arianna LG, Antonio C, Francesco F, Michele K, Giovanni S et al. The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre. Clin Endocrinol (Oxf) 2002;56:247-52.
19. Huysmans DA, Nieuwlaat WA, Erdtsieck RJ, Schellekens AP, Bus JW, Bravenboer B et al. Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter. J Clin Endocrinol Metab 2000;85:3592-6.
20. Nieuwlaat WA, Huysmans DA, van den Bosch HC, Sweep CG, Ross HA, Corstens FH et al. Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter. J Clin Endocrinol Metab 2003;88(7):3121-9.
21. Duick DS, Baskin HJ. Utility of recombinant human thyrotropin for augmentation of radioiodine uptake and treatment of nontoxic and toxic multinodular goiters. Endocr Pract 2003;9:204-9.
22. Silva MN, Rubio IG, Romao R, Gebrin EM, Buchpiguel C, Tomimori E et al. Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres. Clin Endocrinol (Oxf) 2004;60:300-8.
23. Albino CC, Mesa CO, Jr., Olandoski M, Ueda CE, Woellner LC, Goedert CA et al. Recombinant human thyrotropin as adjuvant in the treatment of multinodular goiters with radioiodine. J Clin Endocrinol Metab 2005;90:2775-80.
24. Cohen O, Ilany J, Hoffman C, Olchovsky D, Dabhi S, Karasik A et al. Low-dose recombinant human thyrotropin-aided radioiodine treatment of large, multinodular goiters in elderly patients. Eur J Endocrinol 2006;154:243-52.
25. Paz-Filho GJ, Mesa-Junior CO, Olandoski M, Woellner LC, Goedert CA, Boguszewski CL et al. Effect of 30 mCi radioiodine on multinodular goiter previously treated with recombinant human thyroid-stimulating hormone. Braz J Med Biol Res 2007;40:1661-70.
26. Nielsen VE, Bonnema SJ, Boel-Jorgensen H, Veje A, Hegedus L. Recombinant human thyrotropin markedly changes the 131I kinetics during 131I therapy of patients with nodular goiter: an evaluation by a randomized double-blinded trial. J Clin Endocrinol Metab 2005;90:79-83.
27. Paz-Filho GJ, Graf H. Recombinant human thyrotropin in the management of thyroid disorders. Expert Opin Biol Ther 2008;8:1721-32.
28. Albino CC, Paz-Filho G, Graf H. Recombinant human TSH as an adjuvant to radioiodine for the treatment of type 1 amiodarone-induced thyrotoxicosis (AIT). Clin Endocrinol (Oxf) 2009;70:810-1.
29. Bogazzi F, Tomisti L, Ceccarelli C, Martino E. Recombinant human TSH as an adjuvant to radioiodine for the treatment of type 1 amiodarone-induced thyrotoxicosis: a cautionary note. Clin Endocrinol (Oxf) 2010;72:133-4.
30. Fugazzola L, Persani L, Mannavola D, Reschini E, Vannucchi G, Weber G et al. Recombinant human TSH testing is a valuable tool for differential diagnosis of congenital hypothyroidism during L-thyroxine replacement. Clin Endocrinol (Oxf) 2003;59:230-6.
31. Resende M, Corbo R, Vaisman M. The effect of recombinant human TSH on 123I thyroid uptake after intravenous iodide contrast agent. Nucl Med Commun 2010;31:315-9.
32. Nieuwlaat WA, Hermus AR, Sivro-Prndelj F, Corstens FH, Huysmans DA. Pretreatment with recombinant human TSH changes the regional distribution of radioiodine on thyroid scintigrams of nodular goiters. J Clin Endocrinol Metab 2001;86:5330-6.
33. Hanscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 2006;47:648-54.
34. Giusti M, Cappi C, Santaniello B, Ceresola E, Augeri C, Lagasio C et al. Safety and efficacy of administering 0.2 mg of recombinant human TSH for two consecutive days as an adjuvant to therapy with low radioiodine doses in elderly out-patients with large nontoxic multinodular goiter. Minerva Endocrinol 2006;31:191-209.
35. Nielsen VE, Bonnema SJ, Boel-Jorgensen H, Grupe P, Hegedus L. Stimulation with 0.3-mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign nontoxic nodular goiter: a prospective randomized double-blind trial. Arch Intern Med 2006;166:1476-82.
36. Bonnema SJ, Nielsen VE, Boel-Jorgensen H, Grupe P, Andersen PB, Bastholt L et al. Improvement of goiter volume reduction after 0.3 mg recombinant human thyrotropin-stimulated radioiodine therapy in patients with a very large goiter: a double-blinded, randomized trial. J Clin Endocrinol Metab 2007;92:3424-8.
37. Bonnema SJ, Bertelsen H, Mortensen J, Andersen PB, Knudsen DU, Bastholt L et al. The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function. J Clin Endocrinol Metab 1999;84:3636-41.
38. Fast S, Hegedus L, Grupe P, Nielsen VE, Bluhme C, Bastholt L et al. Recombinant human thyrotropin-stimulated radioiodine therapy of nodular goiter allows major reduction of the radiation burden with retained efficacy. J Clin Endocrinol Metab 2010;95:3719-25.
39. Cubas ER, Paz-Filho GJ, Olandoski M, Goedert CA, Woellner LC, Carvalho GA et al. Recombinant human TSH increases the efficacy of a fixed activity of radioiodine for treatment of multinodular goitre. Int J Clin Pract 2009;63:583-90.
40. Cardia MS, Rubio IG, Medeiros-Neto G. Prolonged follow-up of multinodular goitre patients treated with radioiodine preceded or not by human recombinant TSH. Clin Endocrinol (Oxf) 2006;64:474.
41. Huysmans DA, Hermus AR, Corstens FH, Barentsz JO, Kloppenborg PW. Large, compressive goiters treated with radioiodine. Ann Intern Med 1994;121:757-62.
42. Bonnema SJ, Nielsen VE, Boel-Jorgensen H, Grupe P, Andersen PB, Bastholt L et al. Recombinant human thyrotropin-stimulated radioiodine therapy of large nodular goiters facilitates tracheal decompression and improves inspiration. J Clin Endocrinol Metab 2008;93:3981-4.
43. Watt T, Hegedus L, Groenvold M, Bjorner JB, Rasmussen AK, Bonnema SJ et al. Validity and reliability of the novel thyroid-specific quality of life questionnaire, ThyPRO. Eur J Endocrinol 2010;162:161-7.
44. Nieuwlaat WA, Hermus AR, Ross HA, Buijs WC, Edelbroek MA, Bus JW et al. Dosimetry of radioiodine therapy in patients with nodular goiter after pre-treatment with a single, low dose of recombinant human thyroid-stimulating hormone. J Nucl Med 2004;45:626-33.
45. Barca MF, Gruppi C, Oliveira MT, Romao R, Cardia MS, Rubio I et al. Cardiovascular assessment of hyperthyroid patients with multinodular goiter before and after radioiodine treatment preceded by stimulation with recombinant human TSH. Endocrine 2007;32:175-81.
46. Romao R, Rubio IG, Tomimori EK, Camargo RY, Knobel M, Medeiros-Neto G. High prevalence of side effects after recombinant human thyrotropin-stimulated radioiodine treatment with 30 mCi in patients with multinodular goiter and subclinical/clinical hyperthyroidism. Thyroid 2009;19:945-51.
47. Metso S, Jaatinen P, Huhtala H, Luukkaala T, Oksala H, Salmi J. Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin Endocrinol (Oxf) 2004;61:641-8.
48. Ceccarelli C, Bencivelli W, Vitti P, Grasso L, Pinchera A. Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years' retrospective study. Clin Endocrinol (Oxf) 2005;62:331-5.
49. Huysmans AK, Hermus RM, Edelbroek MA, Tjabbes T, Oostdijk, Ross HA et al. Autoimmune hyperthyroidism occurring late after radioiodine treatment for volume reduction of large multinodular goiters. Thyroid 1997;7:535-9.
50. Nygaard B, Knudsen JH, Hegedus L, Scient AV, Hansen JE. Thyrotropin receptor antibodies and Graves' disease, a side-effect of 131I treatment in patients with nontoxic goiter. J Clin Endocrinol Metab 1997;82:2926-30.
51. Chiovato L, Fiore E, Vitti P, Rocchi R, Rago T, Dokic D et al. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab 1998;83:40-6.
52. Rubio IG, Perone BH, Silva MN, Knobel M, Medeiros-Neto G. Human recombinant TSH preceding a therapeutic dose of radioiodine for multinodular goiters has no significant effect in the surge of TSH-receptor and TPO antibodies. Thyroid 2005;15:134-9.